On October 31, 2025, Mabpharm Limited (2181) designated an existing independent non-executive director, Dr. Zhang Yanyun, as Lead Independent Non-Executive Director. According to the announcement, this position does not confer additional liability but is intended to facilitate communication among independent non-executive directors, the broader board, and shareholders, particularly minority shareholders.

On the same date, the company adjusted the composition of its nomination committee. Executive Director Dr. Qian Weizhu joined as a committee member, while Executive Director Mr. Tao Jing stepped down from that role. The committee now comprises two independent non-executive directors, Mr. Guo Liangzhong and Dr. Zhang, alongside Dr. Qian. Mr. Guo continues to serve as its chairman. These changes were made in response to updated listing rules and corporate governance guidelines effective July 1, 2025, aiming to enhance the board’s overall effectiveness and diversity.